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idwest universities have become research powerhouses in their own right, 
but large centralized investments to enable competitive positions in capital 
intensive activities such as drug discovery and licensing have remained 
generally at larger universities that exist typically along the coasts. Here we propose 
a new regional collaboration in cloud bio-computing, shared core facility support, 
transgenic animal model development, and clinical trials that will compete 
successfully with other drug discovery activities elsewhere in the United States, and 
throughout the world. The west-central region of Missouri and the eastern region of 
Kansas have successfully established themselves internationally through regional 
development non-profits as the world’s ‘Animal Health Corridor’. Here we propose 
to follow a similar international marketing strategy to gain recognition as a center for 
human health research and drug discovery.  
 
This will become possible only 
when truly comprehensive and 
competitive capabilities have been 
established through these essential 
collaborative agreements between major 
Midwest ‘flagship’ research universities. 
It is essential that this effort to secure 
major drug development deals does not 
go forward until all capabilities have 
been established to make a clearly 
competitive value proposition to the 
pharmaceutical industry. 
Introduction  
Over the last several decades the 
University of Missouri (MU) has 
invested extensively in the basic 
biosciences, in comparative medicine, 
and in transgenic technologies for 
research animal model development. 
Over this same period the University of 
Kansas (KU) has become very strong in 
clinical trial development for 
pharmaceuticals. This naturally leads to 
an opportunity to build on each 
institution’s strengths collaboratively as 
we build a world-leading capability in 
bio-innovation and pharmaceutical 
development in human health care. 
Many other institutions in the greater 
Kansas City area, including UMKC, the 
major hospitals, and the Kansas City 
University of Medicine and Bioscience 
(KCUMB), and for-profit firms, all offer 
specific expertise that will greatly enable 
the ability within the Greater Kansas 
City Region to compete with other bio-
innovation centers around the world. 
Children’s Mercy Hospital has 
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established itself as a center for personal 
medicine, and St. Luke’s Hospital is 
renowned for their world-class program 
in stroke prevention and recovery, to 
include the development of highly 
innovative catheter systems to remove 
threatening blood clots from the 
circulatory system near the base of the 
brain. KCUMB currently trains more 
licensed physicians than any other 
educational institution in Missouri, and 
they have developed optimized custom 
facilities to support human medical 
trials. These outstanding capabilities, 
coupled with the emergence of a new 
emphasis on regionalism that is 
discussed in detail below, promise to 
create the environment necessary for this 
region to emerge as the point of choice 
for drug and human health care 
development world-wide within the 
next five years. This, coupled with the 
expanded regional marketing ability of 
the Kansas City Area Development 
Council (KCADC), which successfully 
branded this region as the Animal 
Health Corridor world-wide, all indicate 
that this success is eminently achievable 
once the regional development has 
expanded to assure a competitive value 
proposition in drug discovery to the 
pharmaceutical industry.  
The essential aspect of this regional 
emergence is that all partners remain 
focused on the outcome of such a 
successful collaboration. The issue must 
never become ‘who is getting more than 
whom’ in a particular drug development 
deal, but rather the collective best 
allocation of regional resources to out-
perform competition along the Coasts. 
This will require complete transparency 
in a non-profit organization with even 
and equal representation from all 
participatory institutions. This non-
profit would transparently solicit, 
structure, and propose the parsing of 
these major deals based on proven 
ability to perform. It is the ability to 
represent the collective capabilities of all 
institutions concerned that will make the 
Midwest Region more attractive than 
existing drug discovery operations 
elsewhere in the United States. We at 
MU have been approached by numerous 
international investment groups that are 
interested in developing a high-tech 
based drug development effort on the 
MU campus. Such regional efforts will 
succeed over the competition if the 
complementary strengths across the 
Midwest Region are effectively brought 
together in a single, external marketing 
operation. Nothing will prevent each 
institution’s efforts to solicit other 
business alone simultaneously, but all 
institutions will need to agree not to 
interfere or compete with a particular 
deal that is being negotiated by the non-
profit on behalf of all institutions.   
Regional Cloud Computing  
The KCALSI has worked closely 
with many Chief Information Officers 
from institutions within the Kansas City 
Area to propose a mutual investment in 
cloud bio-computing, which would meet 
a major need within the Region for drug 
discovery, and other applications. This 
effort, which has been led by Dr. Gary 
Allen, CIO of MU, will soon propose a 
structure for such a shared investment 
across the Midwest Region. Other areas 
of the United States have found that 
such cooperative investments achieve a 
better economy of scale, and we 
anticipate that this will be realized in the 
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Great Plains Network as well. IBM has 
expressed interest in this, and MU has 
recently won a SUR (Shared University 
Research) Award to develop cloud 
computing. Further, I have joined with 
the MU Development staff and some of 
our lead research faculty members in a 
detailed meeting with Mark Dean, Vice 
President of IBM, and we have agreed 
that the development of cloud bio-
computing is an important shared goal 
of both IBM and MU. Following this 
meeting and after further discussions 
with those mentioned above, MU’s CIO 
Gary Allen, has structured and led a 
group of CIOs from the University of 
Kansas, Kansas State University, 
Mizzou, and the University of Missouri 
System to develop an expanded regional 
commitment to cloud biocomputing. 
Others, including Dr. John Wegman, 
Head of Computer Science, and Dr. 
Frank Lee, a Systems Architect, both of 
IBM, have worked extensively with MU 
and with the CIOs working through 
KCALSI to help define a detailed 
technical vision of what such a cloud 
biocomputing effort may become in the 
future.  
The development of high-end 
computing for computational drug 
discovery, interface data acquisition, 
management, for bioinformatics of 
massive amounts of genetic and 
proteomic data, and applications 
individually to the advent of 
personalized medicine, are a current 
critical missing component of our efforts 
to develop a Midwest engine in drug 
discovery. Led by Dr. Gary Allen, the 
CIOs from Kansas State University, 
University of Kansas (both their Medical 
Campus in Kansas City, Kansas and 
their main campus at Lawrence), 
Mizzou, and the University of Missouri 
System have considered the advantages 
carefully, and they list the following 
advantages of such high-end computing 
to the biosciences and health care of the 
Midwest Region:  
• Evaluating hundreds of thousands 
of molecules to find the most 
promising candidates for cancer 
therapies, 
• Analyzing huge data sets that are 
derived from modern medical and 
biological imaging technologies, 
and medical records, 
• Modeling how complex biological 
systems operate and how changes 
in these systems result in human 
and animal disease,  
• Understanding how the 
uniqueness of an individual’s 
genetic code can be used to 
optimize medical treatments 
through personalized medicine, 
and 
• Developing designs for nano-
technology-based health products 
ranging from microscopic disease 
screening laboratories to new 
formulations for the formulating 
and delivering therapeutic agents.  
A proposal request for funding is 
being prepared by many major research 
universities in Kansas and Missouri. 
Hopefully this Great Plains Cloud 
Computing effort will fill this regional 
need.  
Shared Core Facilities  
The chief research officers of all 
eleven institutions of higher education, 
and others from major research non-
profits and corporations that attended 
the Life Sciences Summit in Kansas City 
in March, 2010, met to address what will 
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be needed to realize the emergence of 
the Midwest Region. We agreed at that 
meeting to convene a meeting of the 
Core Research Facility Managers from 
each of our Institutions. Dr. Mark 
McIntosh, Director of the MU Core 
Facilities and Chair of the Department of 
Immunology in the Medical School, will 
coordinate this meeting in the Kansas 
City area this Fall. The intention of this 
meeting will be to determine what core 
facilities may be shared between 
institutions, and what facilities may be 
made available to small start-up 
companies on a cost recovery basis to 
make the Midwest Region more 
attractive to companies in the 
biosciences that are considering locating 
in this Region.  
Currently MU supports a fully 
functional Core research capability that is 
available to enhance the research activities 
of all our investigators, and many of which 
are available to collaborative researchers 
across the state and throughout the world. 
Some of these core facilities report directly to 
the Office of Research at MU, and they are 
documented in detail through web links at: 
http://research.missouri.edu/division/cores.
htm. Note that the 800 MHz Nuclear 
Magnetic Resonance instrument, which is 
used to infer molecular structure, is unique 
within the State of Missouri. Other 
outstanding Core capabilities are located 
within our Interdisciplinary Research 
Centers, reporting to the Office of Research 
through their respective Centers (please see: 
http://research.missouri.edu/division/center
s.htm). Many of these core capabilities are 
unique within Missouri, including the 
activation and neutron scattering services 
through MURR (our research reactor at 
MU), a state-of-the-art mass spectrometer 
and x-ray diffractometer at the International 
Institute for Nano and Molecular Medicine 
(note: we also have mass spectrometers in 
Proteomics and X-ray diffraction in the 
Structural Biology Core, as well as access to 
the Advanced Light Source synchrotron at 
Berkeley), and state-of-the-art in vivo 
imaging facilities for tiny blood vessels and 
other microscopic tissue at the Dalton 
Cardiovascular Research Center and for 
whole animal imaging at the VA 
Biomolecular Imaging Center. The Bond 
Life Sciences Center has developed many 
new capabilities, including a laser-based 
opto-photonic system that can detect a 
single metastasized melanoma cancer cell in 
blood serum, and a new application of 
an existing compound that is literally 
thousands of time more effective at 
treating AIDS than other compounds in 
the same primate that was responsible 
for the cross-over infection in humans. 
The Regional Biocontainment 
Laboratory (RBL) provides unique 
facilities for inhalation toxicology 
studies in laboratory animals, and in 
imaging laboratory animals in a 
Biosafety Level 3 Facility. The 
Interdisciplinary Plant Group (IPG) at 
MU is among the very best in the world, 
with thirteen of their faculty members 
having been elevated to Fellow of the 
AAAS. This IPG is responsible for the 
first sequence of the soybean genome, 
and derived technology from this 
advance is being used to develop new 
strains of soybeans and other crops that 
are resistant to drought and parasites, 
which increase the value of our harvests 
by billions of dollars per year. The 
Transgenic Animal Core Facility and 
three NIH-funded Animal Resource 
Centers (Mutant Mouse, Rat and Swine) 
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at MU are world-class, and supply 
knock-out genetic technology to 
researchers throughout the world who 
need an animal model that is closer to 
human where it counts in the pursuit of 
the development of therapies for human 
diseases, such as the swine cystic fibrosis 
model.   
Other unique research Core facilities 
and capabilities exist throughout the 
State of Missouri: The Missouri 
University of Science and Technology 
(MS&T) in Rolla operates the state’s only 
gallium focused ion beam device, which 
is able to cut and shape materials at the 
atomic level. MS&T also hosts an 
outstanding capability for analyzing and 
optimizing the design of the electric 
power grid across the United States. 
UMKC has world-class programs in 
both stroke prevention and treatment, 
and in the study and development of 
mineralized tissues for dentistry and 
orthopedic surgery. Both the Midwest 
Research Institute in Kansas City, and 
the Danforth Plant Sciences Center in St. 
Louis, possess unique capabilities in 
harvesting oil from microscopic algae, 
which promises to be an outstanding 
new source of green energy. Other 
industries, ranging from Honeywell and 
Black and Veech in Kansas City, to 
Monsanto and Boeing in St. Louis, 
continuously develop new commercial 
technologies in collaboration with MU 
that advance the human condition.  
MU has led the way in encouraging 
a broad sharing of our core capabilities 
across Missouri. MU currently provides 
genetic sequencing support for several 
Missouri academic institutions 
including Washington University in St. 
Louis, Missouri State University in 
Springfield and Truman State University 
in Kirksville, and flow cytometry core 
support for Kansas University’s Medical 
Center in Kansas City, Kansas. MU’s 
transgenic cores provide research animal 
technology throughout the world. 
MURR provides more radioisotopes for 
medical applications than any other 
reactor within the USA, and many 
companies, such as ABC Laboratories 
and those in the MU Life Sciences 
Incubator, routinely use the MU Core 
facilities on a full cost recovery basis. 
Project: Mizzou, which is a collaboration 
between seven major administrative 
offices at MU, has been developing a 
plan to permit these core facilities to be 
utilized broadly by outside 
organizations, including businesses, 
non-profits, and other universities. The 
Life Sciences Summit, led by MU and 
hosted by the UMKC campus, set the 
stage for broad regional collaborations 
across many states, and initiated the 
Midwest Bio-Innovation Belt.  
In addition, a commercial entity 
called ABC Labs currently conducts 
NMR-based molecular stability 
measurements within the MU core 
facilities, and they are working closely 
with MU to expand this core utilization 
to proteomics and possibly other 
applications in the future. It is important 
to note that these collaborations with 
ABC Labs has helped MU substantially 
in the development of Good Laboratory 
Practice (GLP) and Good Manufacturing 
Practice (GMP) standards within the MU 
Research Reactor (MURR) core facilities 
at MU. These standards of GMP and 
GLP are essential to industry in order to 
support their efforts to secure 
intellectual property, and the 
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establishment of these very demanding 
standards within our academic cores, 
provide an opportunity for excellent 
experiential learning for our students 
who aspire to move into commercial 
laboratory research following their 
degree awards. Such efforts within our 
cores provide MU with a unique 
advantage in our quest to engage more 
substantially with industry.  These GLP / 
GMP standards require roughly one 
scientist-year of dedicated effort to 
establish for each core capability, so any 
university laboratory that makes such an 
investment should have a long-term 
commitment to industrial collaborative 
research to assure a recovery of this 
extensive investment. MU’s investment 
in these commercial laboratory 
standards are a central part of our 
commitment to fee-for-service work 
arrangements with industry, which in 
turn makes MU and the Midwest Region 
much more attractive for smaller start-
up biotechnology companies, as well as 
to more established firms such as ABC 
Labs. 
Conclusions, and Next Steps  
Once a substantial capability in both 
bioscience cloud computing and in 
shared core laboratory facilities are 
established within the Midwest Region, 
the next step will be to get the leading 
investigators who are active in drug 
discovery at our various institutions and 
at KCALSI to meet at each other’s 
locations with a very concentrated focus 
on how we can specifically build on each 
institutions’ strengths to make the 
Midwest Region more competitive than 
other locations across the United States 
for all aspects of drug discovery. Once 
such a general agreement is in place 
between the participating institutions, 
then the next step will be to take a 
comprehensive approach to define the 
Midwest Region as the optimal location 
for major drug discovery. The close 
collaborations that emerge from this 
effort will likely lead to new regional 
opportunities for additional work 
beyond drug discovery.  
